Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews

The Lancet

Volumn 378, Issue 9791, 2011, Pages 571-583

  Nelson, Paul K ^a   Mathers, Bradley M ^a   Cowie, Benjamin ^b   Hagan, Holly ^c   Des Jarlais, Don ^d   Horyniak, Danielle ^e   Degenhardt, Louisa ^e,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c NEW YORK UNIVERSITY   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e BURNET INSTITUTE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS C ANTIBODY;

DRUG USE; EMBASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDLINE; PEER REVIEW; PREVALENCE; PRIORITY JOURNAL; PSYCINFO; REVIEW; SEROLOGY; SYSTEMATIC REVIEW;

EID: 80051676859     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61097-0     Document Type: Article

References (37)

1. BM Mathers, L Degenhardt, B Phillips et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review Lancet 372 2008 1733 1745
2. Degenhardt L, Hall W. The extent of illicit drug use, dependence, and their contribution to the global burden of disease. Lancet (in press).
3. M Donoghoe, A Wodak Health and social consequences of injecting drug use G Stimson D Des Jarlais A Ball Drug injecting and HIV infection: global dimensions and local responses 1998 UCL Press London, UK 42 57
4. HS Te, DM Jensen Epidemiology of hepatitis B and C virus: a global overview Clin Liver Dis 14 2010 1 21
5. GJ Dore, AJ Freeman, M Law, JM Kaldor Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 17 2002 423 430 (Pubitemid 34534080)
6. W Limberg Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview J Jager W Limburg M Kretzschmar M Postma L Wiessing Hepatitis C and injecting drug user: impact, costs and policy options 2004 European Monitoring Centre for Drugs and Drug Addiction Lisbon, Portugal 21 38
7. MJ Alter Epidemiology of hepatitis C virus infection World J Gastroenterol 13 2007 2436
8. JF Perz, GL Armstrong, LA Farrington, YJF Hutin, BP Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538 (Pubitemid 44307383)
9. D Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepatitis 11 2004 97 107 (Pubitemid 38365759)
10. World Health Organization Resolution A63/15: Viral hepatitis. 63rd World Health Assembly http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-15-en.pdf (accessed May 24, 2011).
11. OS Levine, D Vlahov, KE Nelson Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions Epidemiol Rev 16 1994 418 436
12. N Walsh, A Verster, A Doupe, M Vitoria, Y-R Lo, ST Wiersma The silent epidemic: responding to viral hepatitis among people who inject drugs C Cook The global state of harm reduction 2010: key issues for broadening the response 2010 International Harm Reduction Association London, UK 71 80
13. C Aceijas, T Rhodes Global estimates of prevalence of HCV infection among injecting drug users Int J Drug Policy 18 2007 352 358 (Pubitemid 47374507)
14. H Hagan, ER Pouget, DC Des Jarlais, C Lelutiu-Weinberger Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place Am J Epidemiol 168 2008 1099 1109
15. KH Jacobsen, ST Wiersma Hepatitis A virus seroprevalence by age and world region, 1990 and 2005 Vaccine 28 2010 6653 6657
16. SA Hughes, H Wedemeyer, PM Harrison Hepatitis delta virus Lancet 378 2011 73 85
17. D Moher, A Liberati, J Tetzlaff, DG Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
18. R Stern, H Hagan, C Lelutiu-Weinberger et al. The HCV synthesis project: scope, methodology and preliminary results BMC Med Res Methodol 18 2008 341 351
19. H Ali, B Calabria, B Phillips et al. Searching the grey literature to access information on drug, alcohol and HIV/AIDS research: an update. NDARC Technical Report No. 314 http://ndarc.med.unsw.edu.au/NDARCWeb.nsf/resources/ TR313-317/$file/TR+314.pdf (accessed May 27, 2011).
20. L Degenhardt, C Bucello, B Calabria et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews Drug Alcohol Depend 2011 10.1016/j.drugalcdep.2010.11.032 published online March 4.
21. G Matthews, GJ Dore The epidemiology of HIV and viral hepatitis coinfection. In: Dore GJ, Sasadeusz J, eds. Coinfection - HIV and viral hepatitis: a guide for clinical management http://www.hep.org.au/documents/ Coinfection-680KB.pdf (accessed May 27, 2011).
22. E von Elm, DG Altman, M Egger et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet 370 2007 1453 1457
23. BM Mathers, L Degenhardt, H Ali et al. HIV prevention, treatment and care for people who inject drugs: a systematic review of global, regional and country level coverage Lancet 375 2010 1014 1028
24. UN Population Division World population prospects: the 2008 revision 2009 United Nations New York, USA
25. J Kimber, L Copeland, M Hickman et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment BMJ 341 2010 c3172
26. International Harm Reduction Association Poor access to HCV treatment is undermining Universal Access. A briefing note to the UNITAID board http://www.ihra.net/files/2010/06/17/HCVBriefingPaperEnglish.pdf (accessed May 14, 2011).
27. T Swan The hepatitis C treatment pipeline report http://www. treatmentactiongroup.org/uploadedFiles/About/Publications/TAG-Publications/2011/ HCV20pipeline20201120final.pdf (accessed June 18, 2011).
28. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid dependent people: cohort study. Addiction (in press).
29. N Palmateer, J Kimber, M Hickman, S Hutchinson, T Rhodes, D Goldberg Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews Addiction 105 2010 844 859
30. NK Martin, P Vickerman, M Hickman Mathematical modelling of hepatitis C treatment for injecting drug users J Theor Biol 274 2011 58 66
31. J Amin, MG Law, M Bartlett, JM Kaldor, GJ Dore Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study Lancet 368 2006 938 945 (Pubitemid 44331386)
32. MJ Alter Epidemiology of viral hepatitis and HIV co-infection J Hepatol 44 2006 S6 S9
33. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53: 348-56.
34. EE Mast, HS Margolis, AE Fiore et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States MMWR Recomm Rep 54 2005 1 25
35. DR Hunt, S Saab Viral hepatitis in incarcerated adults: a medical and public health concern Am J Gastroenterol 104 2009 1024 1031
36. DT Kenny, PK Nelson Young offenders on community orders: health, welfare and criminogenic needs http://hdl.handle.net/2123/2282 (accessed June 18, 2011).
37. B Cowie The linguistic demography of Australians living with chronic hepatitis B Aust N Z J Public Health 35 2011 12 15